Back
Moderna Inc (MRNA)
BiotechnologyMRNA · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$145.13
+8.86%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-7.25
ROE
-36.6%
Gross margin
-69.9%
Debt/Equity
0.18x
Revenue growth
260.2%
Moderna Inc — company intelligence
Earnings surprises
Q2 2026$-1.97 vs $-2.12 est+7.3%
Q1 2026$-3.40 vs $-4.04 est+15.8%
Q4 2025$-2.11 vs $-2.70 est+21.7%
Q3 2025$-0.51 vs $-2.15 est+76.3%
Analyst consensus · 30 analysts
9 Buy18 Hold3 Sell
Updated Aug 22, 2026
Insider activity · 90 days
5 buys14 sellsnet -500,252 shares
Bancel Stephaneother 64,928 · Aug 6, 2026
Bancel Stephaneother 187,541 · Aug 6, 2026
Bancel Stephaneother 252,469 · Aug 6, 2026
Recent SEC filings
4 — Insider transaction reportAug 7, 2026
10-Q — Quarterly reportJul 31, 2026
8-K — Material event reportJul 31, 2026
Latest news
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? — Yahoo · 2w ago
Moderna: I'm Still On Sell, But Here's What Would Change My Mind — SeekingAlpha · 2w ago
Moderna (MRNA) Q2 2026 Earnings Call Transcript — Yahoo · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.